Le Lézard
Classified in: Health
Subject: NPT

American Society of Pharmacovigilance Amplifies Coordinated Efforts on Third Annual National Adverse Drug Event Day


HOUSTON, March 20, 2024 /PRNewswire/ -- Almost one million Americans have died of adverse drug events, many avoidable, in the three year history of National Adverse Drug Event (ADE) Day. The American Society of Pharmacovigilance (ASP) is proud to spotlight the unified efforts of healthcare organizations nationwide to address this public health crisis. Today, ASP alongside numerous partners, reinvigorates the commitment to advancing drug safety through a collective push towards reducing ADEs, the fourth leading cause of death in the United States. The society encourages individuals and professionals alike to visit fourthcause.org to deepen their understanding and participation in this critical cause.

National ADE Day has become a cornerstone event for rallying healthcare providers, patients, and policymakers around the vital issue of medication safety. Through coordinated messaging and shared initiatives, this year's observance underscores the power of collaboration in amplifying the impact of pharmacovigilance practices and promoting a culture of safety and transparency within the healthcare system.

The theme of this year's National ADE Day centers on community and collaboration, highlighting the importance of every voice in the fight against ADEs. Through the central hub at fourthcause.org, ASP aims to provide a platform for sharing resources, experiences, and strategies to mitigate the risks associated with adverse drug events.

"Reflecting on the progress since the inception of National ADE Day, we're inspired by the collective action and heightened awareness within our communities," said Benjamin Brown, ASP Executive Director. "This year, we emphasize the strength of our united efforts and encourage everyone to contribute to this critical dialogue by visiting fourthcause.org. Together, we can continue to make strides towards safer medication practices and ultimately, save lives."

As part of the day's activities, healthcare organizations across the country are hosting webinars, workshops, and public awareness campaigns, all accessible through fourthcause.org. These events serve as a call to action for healthcare professionals, patients, and the public to engage with the latest research, tools, and guidelines for preventing ADEs.

The ASP invites all stakeholders to join this national movement by visiting fourthcause.org to learn more, share their stories, and access valuable resources. Through collaboration and education, we can achieve a future where adverse drug events are no longer a leading cause of harm in healthcare settings.

List of supporting organizations: https://stopadr.org/blog/national-adverse-drug-event-ade-awareness-day-a-united-front-in-the-fight-against-ades

About the American Society of Pharmacovigilance
The American Society of Pharmacovigilance (ASP) is a 501(c)(3) nonprofit dedicated to reducing adverse drug events (ADEs), a leading cause of suffering and mortality in the U.S. As a national network, ASP is open to healthcare professionals across all disciplines, united in the mission to address the fourth leading cause of death in the country. Through collaboration and innovation, ASP aims to enhance patient safety and healthcare quality by mitigating the risks associated with ADEs. Our members are at the forefront of research, education, and advocacy, striving to create a more responsive and preventative healthcare system. For more information on how to join or support our mission, visit our www.stopadr.org.  

Media Contact
Sara Rogers
President
American Society of Pharmacovigilance
[email protected]
469-939-8475

SOURCE American Society of Pharmacovigilance


These press releases may also interest you

at 09:40
The "Global RNAi Therapeutics Market (By Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering. The global RNAi therapeutics...

at 09:31
RSi, a privately held revenue cycle management service provider that exclusively services hospitals and healthcare systems, has been awarded five 2024 Top Workplace honors. The awards were recently announced by the HR employee engagement technology...

at 09:30
Michael Karlfeldt, ND, PhD, Nasha Winters, ND, FABNO, LAc, DiplOM, and 40+ Experts Gather to Share the Latest Breakthroughs in Cancer Treatment Key Takeaways: The Cancer Breakthroughs Summit 2.0 aims to transform fear into confidence by providing...

at 09:26
Omeza®, a regenerative skincare company that develops marine-based therapies for wounds that are hard to treat, today presented final data from a diabetic foot ulcer (DFU) clinical trial showing that Omeza® OCMtm plus offloading of weight on the...

at 09:25
The "China Biological Reagents Market (Molecular Biology Reagents, Proteins and Cell Reagents): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering. The China biological...

at 09:25
Illumina, Inc. today announced that its executives will be speaking at the following investor conference: RBC 2024 Global Healthcare Conference on May 14, 2024Fireside chat at 5:30am Pacific Time (8:30am Eastern Time)The webcast can be accessed...



News published on and distributed by: